INNOCARE (09969) saw its shares rise more than 4% in late trading. At the time of writing, the stock was up 3.96%, trading at HK$12.08, with a turnover of HK$44.72 million. The movement follows the company's announcement that patient enrollment has been completed for a registrational Phase 3 clinical trial. The trial is evaluating the company's self-developed novel BCL2 inhibitor, mesutoclax (ICP-248), in combination with the BTK inhibitor orelabrutinib as a first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Public information indicates that mesutoclax is a novel oral, highly selective BCL2 inhibitor. Beyond first-line treatment for CLL/SLL, the development of mesutoclax is being accelerated for a registrational clinical trial targeting mantle cell lymphoma following resistance to BTK inhibitors. This program has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration. Furthermore, clinical studies of mesutoclax for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are advancing both in China and globally.